His Royal Highness the Duke of Gloucester visited the University of Oxford on Thursday 24th July to tour two of its leading medical research centres: the Clinical BioManufacturing Facility and the laboratories of the Oxford Vaccine Group (OVG) and Pandemic Sciences Institute (PSI), located on the University\u2019s Old Road Campus.
The University of Oxford held a groundbreaking ceremony on Tuesday 24 June to celebrate the start of construction of the Cyrus Poonawalla Vaccines Research Building. The ceremony marks a significant milestone in Oxford\u2019s mission to counter and constrain global health threats.
The University of Oxford\u2019s vaccine to protect people from deadly Nipah virus has been granted support from the PRIority MEdicines (PRIME) scheme offered by Europe\u2019s medicines regulator, the European Medicines Agency (EMA). It is the first UK academic institution to be awarded this designation.
Simon Draper, Professor of Vaccinology and Translational Medicine at the Department of Paediatrics and Kavli Institute for Nanoscience Discovery, has been elected as a Fellow to the Academy of Medical Sciences, it has been announced today.
The outcome of a trial published in Science Translational Medicine, shows encouraging results for a new vaccine targeting group B meningococcus (MenB), a significant cause of meningococcal disease worldwide, and establishes proof-of-concept in humans that a gene-based vaccine platform can induce protective antibody responses against bacteria.
Researchers in Oxford have found structures of immune cells in the gut that may be driving the response to gluten in people with coeliac disease and could provide a target for future therapies.
Results of two parallel studies show that one in four African children hospitalised with malaria and coma have an additional infection, and that giving antibiotics with antimalarials could help reduce death rates of comatose children.
The chapel facade of Magdalen College was lit up ahead of the commemoration of Rare Disease Day (RDD) which was celebrated on Friday 28th February 2025. The celebration is held on 29th February in a leap year as it is the rarest day in the year.
The Pandemic Sciences Institute, including principal investigators from the Oxford Vaccine Group, has signed a memorandum of understanding with Institut Pasteur de Dakar (IPD) to become a partner institution. PSI and Institut Pasteur de Dakar (IPD) will cooperate on developing vaccines and rapid diagnostics \u2013 as well as strengthening workforce in the vaccinology, clinical trials and biomanufacturing sectors.
Research by experts at the Department of Paediatrics, and published in the European Journal of Paediatrics shows that early interventions of support to the development of children living in disadvantaged settings, can significantly improve their neurodevelopmental outcomes during early childhood.
Oxford University researchers are to lead and co-lead on two MRC research centres, which are being launched to develop new advanced treatments for currently untreatable diseases.
Results of a clinical trial into a new malaria vaccine candidate (RH5.1/Matrix-M) show it is well-tolerated and offers effective protection against the blood-stage of the disease \u2013 the first inoculation to do so.
Nicky Whiffin, Associate Professor and Sir Henry Dale Fellow at the University of Oxford\u2019s Big Data Institute and Centre for Human Genetics, has been awarded the 2025 Balfour Lecture by the Genetics Society.
Oxford Cancer, the Oxford Vaccine Group and the Pandemic Sciences Institute have announced a new collaboration with Belgian Biotech Innovator, Univercells.
The Ineos Oxford Institute for antimicrobial research (IOI) has awarded over \u00a32m to six projects across the University of Oxford focused on developing new solutions to tackle antimicrobial resistance (AMR), including one at the Oxford Vaccine Group.
Former UK Prime Minister David Cameron has resumed his role as chair of the OHC Advisory Council, a position he originally undertook in October 2023 prior to his appointment as Foreign Secretary.
A single dose of typhoid conjugate vaccine (TCV) offers safe, effective protection against typhoid two years after vaccination in all children, and sustained protection for older children at three to five years post immunisation, according to a report by researchers at the Oxford Vaccine Group and icddr,b. But it also shows a decline in protection at the later timepoints among children vaccinated at younger ages.
A major art installation featuring dramatically upscaled bacteria, viruses and a parasite has been unveiled at Oxford University\u2019s Museum of Natural History to celebrate 30 years of vaccine development by the Oxford Vaccine Group (OVG) which has tackled some of the world\u2019s most deadly diseases.
![\"\"](\"https://www.paediatrics.ox.ac.uk/news/hrh-the-duke-of-gloucester-visits-university-of-oxford2019s-cutting-edge-vaccine-facilities/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n